High-risk metastatic gestational trophoblastic disease

Alan N. Gordon, David M. Gershenson, Larry J. Copeland, Patton B. Saul, John J. Kavanagh, Creighton L. Edwards

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

The clinical course of 61 patients with high-risk metastatic gestational trophoblastic disease was reviewed. Currently, 34 patients (56%) are alive and in complete remission. The survival rate after full-term pregnancy was significantly worse than after any other type of antecedent pregnancy. Analyzing survival by individual high-risk criteria revealed significantly improved survival for those patients with elevated β-human chorionic gonadotropin titer alone when compared with all other high-risk criteria. Fifty-eight percent of patients (14 of 24) primarily treated with alternating-sequential therapy consisting of methotrexate and actinomycin-D experienced a complete remission. Of those patients primarily treated with methotrexate, actinomycin-D, and cyclophosphamide, 63% (20 of 32) achieved a complete remission. Treatment with second-line chemotherapy was largely unsuccessful. Aggressive early treatment is warranted in this group of patients, using multiagent chemotherapy. A search for newer more effective regimens should continue.

Original languageEnglish (US)
Pages (from-to)550-556
Number of pages7
JournalObstetrics and gynecology
Volume65
Issue number4
StatePublished - Apr 1985

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'High-risk metastatic gestational trophoblastic disease'. Together they form a unique fingerprint.

Cite this